465 related articles for article (PubMed ID: 25346016)
1. An update on pharmacotherapy for leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2015 Feb; 16(2):237-52. PubMed ID: 25346016
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging medications for the treatment of leishmaniasis.
Chakravarty J; Sundar S
Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
[TBL] [Abstract][Full Text] [Related]
4. Recent developments and future prospects in the treatment of visceral leishmaniasis.
Sundar S; Singh A
Ther Adv Infect Dis; 2016 Jun; 3(3-4):98-109. PubMed ID: 27536354
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
6. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
7. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
8. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
9. Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral.
Monge-Maillo B; López-Vélez R
Rev Iberoam Micol; 2021; 38(2):101-104. PubMed ID: 34127386
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
[TBL] [Abstract][Full Text] [Related]
11. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
12. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.
Datta A; Podder I; Das A; Sil A; Das NK
Indian J Dermatol; 2021; 66(1):34-43. PubMed ID: 33911291
[TBL] [Abstract][Full Text] [Related]
14. [Management of cutaneous leishmaniasis in adults and children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821
[TBL] [Abstract][Full Text] [Related]
15. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
16. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
17. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
18. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
19. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
20. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
